Gene-editing firms form patent alliance against Editas, Broad
By Max Stendahl,
Boston Business Journal
| 12. 16. 2016
Four biotechs involved in the burgeoning field of gene editing announced a formal patent alliance on Friday that puts them at odds with two Cambridge institutions doing the same, Editas Medicine and The Broad Institute.
The four companies — Berkeley, California-based Caribou Biosciences, ERS Genomics of Ireland, and Cambridge-based firms CRISPR Therapeutics (Nasdaq: CRSP) and Intellia Therapeutics (Nasdaq: NTLA) — all licensed or sublicensed intellectual property regarding CRISPR/Cas9 gene-editing from the same source: biologist Emmanuelle Charpentier, the Regents of the University of California and the University of Vienna.
On the other side of the dispute is Editas (Nasdaq: EDIT), which has been using CRISPR technology developed by Feng Zhang of the Broad Institute.
Charpentier and Zhang have each received patents for CRISPR/Cas9, a method of cutting out and replacing part of a gene that has the potential to revolutionize the treatment of serious genetic disorders. Their backers — UC Berkeley and the Broad, respectively — are currently duking it out in a court case in Virginia before the U.S. Patent and Trademark Office. A decision is expected in coming...
Related Articles
By Ryan Cross, Endpoints News | 08.19.2025
Human eggs are incredibly rare cells. The ovary typically produces only 400 mature eggs across a woman’s life. But biologists in George Church’s lab at Harvard University — a group that’s never content with nature’s limits — just got a...
By Geoffrey A. Fowler, The Washington Post | 07.17.2025
Nearly 2 million people protected their privacy by deleting their DNA from 23andMe after it declared bankruptcy in March. Now it’s back with the same person in charge — and I still don’t trust it.
Nor do the attorneys general...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...
By Alice Park, TIME | 07.08.2025
Rare genetic diseases are challenging for patients and their families—made all the more overwhelming because symptoms tend to appear soon after birth.
To date, there haven’t been many reliable treatment options for these babies. The few that do exist involve...
